Drug intelligence / Profile preview

Hemocare-XT

Development stage: Unknown
Lead developer: MMC Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Hemocare-XT is an oral combination supplement developed and marketed by MMC Pharmaceuticals, primarily indicated for the treatment of iron deficiency anemia and anemia resulting from chronic blood loss or pregnancy. The formulation contains 100 mg of elemental iron and 1.5 mg of folic acid. Elemental iron serves to replenish systemic iron stores necessary for hemoglobin synthesis and oxygen transport, while folic acid acts as an essential cofactor for erythropoiesis and DNA synthesis. Clinical data has demonstrated that treatment with Hemocare-XT leads to significant improvements in hemoglobin levels, particularly in women of reproductive age. It is also used to address mineral deficiencies related to poor nutrition and digestive disorders.

Brand names: Hemocare-XT
Other names: Hemocare XT Tablet

Beyond the preview

Go deeper on Hemocare-XT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemocare-XT.

Explore the full profile